3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Navin Varadarajan of the University of Houston, Kelly Pracht of nVenue, and Atul Varadhachary of Fannin. Photos courtesy

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes two health tech innovators and a sportstech CEO.

Kelly Pracht, CEO and co-founder of nVenue

Kelly Pracht joins the Houston Innovators Podcast to discuss how she's expanded nVenue to new sports. Photo courtesy of nVenue

All though career technologist Kelly Pracht began her entrepreneurial journey with her favorite sport, baseball, she's recently expanded the data-backed, fan-engaging sports betting platform to new sports.

Pract, who spent nearly 20 years designing technologies at Hewlett Packard Enterprise, founded nVenue in 2019 after realizing that, while there's endless data and stats available in baseball, there's nothing that exists for fans to engage in that data in real time. So, she set out to build it herself.

At first, the platform launched as a direct-to-fans platform, but Pracht says on the Houston Innovators Podcast that the company pivoted to B-to-B amid its participation in the Comcast SportsTech accelerator.

"The industry was super hungry for fan engagement and sports betting, and we were one of the only companies that could do it," she says on the show. "We found this huge product-market fit of the whole industry wanting ways to engage and bet in real time." Read more.

Exclusive: 2 Houston health care institutions team up to develop cancer-fighting treatments

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics. Photo via Getty Images

Two Houston organizations announced a new collaboration in a major move for Houston’s biotech scene.

Fannin Partners and the University of Texas MD Anderson Cancer Center have teamed up to develop drugs based on Raptamer, the creation of Fannin company Radiomer Therapeutics.

“Raptamers combine antibody level affinities with desirable physical and pharmacokinetic properties, and a rapid path to clinic,” Dr. Atul Varadhachary, CEO of Radiomer Therapeutics and Fannin managing partner, Varadhachary, explained to InnovationMap in May. “We are deploying this unique platform to develop novel therapies against attractive first-in-class oncology targets.” Read more.

Earlier this year, Varadhachary joined the Houston Innovators Podcast to discuss Fannin's innovation approach and contribution to medical development in Houston. Listen to the episode below.

Navin Varadarajan, M.D. Anderson Professor of William A. Brookshire Chemical and Biomolecular Engineering at University of Houston

The University of Houston's Navin Varadarajan explains that while COVID vaccines prevent advanced disease, they don’t prevent transmission. But he has a solution. Photo via UH

Since the force of COVID-19 hit globally in 2020, scientists have made efficient progress in the fight against it. As Dr. Navin Varadarajan puts it, vaccines have “allowed us to become a society again.”

And he should know, the M.D. Anderson Professor of William A. Brookshire Chemical and Biomolecular Engineering at University of Houston just published back-to-back studies for nasal sprays that combat viruses. One, the NanoSTING therapeutic, has proven effective in treating strains of SARS-CoV-2 and the flu virus. The other, NanoSTING-NS Pan-coronavirus Vaccine is targeted at preventing the transmission of multiple COVID variants altogether.

Why a nasal vaccine? Varadarajan explains that while COVID vaccines prevent advanced disease, they don’t prevent transmission.

“Intramuscular vaccines do not facilitate a component of peer immunity called mucosal immunity, which takes care of these points of entries, these wet surfaces, which can be of the nose and the wet surfaces of the nose, and so they don't prevent transmission,” he tells InnovationMap. “So I can be vaccinated, I pick up a small infection that's confined largely to my nostrils, and I can still pass it on to vulnerable people, the aged, the immunocompromised people who have all the drugs they're taking to fight other things, like cancer patients. And so for them, the vaccines tend to be less efficacious, and if I transfer it to them, unfortunately they can end up in a hospital, right? And so preventing transmission is the way to end this cycle.” Read more.

This uniquely Houston technology is an AI program that allows scientists to understand the functions of cells by evaluating cell activation, killing, and movement. Photo via Getty Images

University of Houston lab reports breakthrough in cancer-detecting technology

making moves

T-cell immunotherapy is all the rage in the world of fighting cancer. A Houston company’s researchers have discovered a new subset of T cells that could be a game changer for patients.

CellChorus is a spinoff of Navin Varadarajan’s Single Cell Lab, part of the University of Houston’s Technology Bridge. The lab is the creator of TIMING, or Time-lapse Imaging Microscopy In Nanowell Grids. It’s a visual AI program that allows scientists to understand the functions of cells by evaluating cell activation, killing, and movement.

Last month, Nature Cancer published a paper co-authored by Varadarajan entitled, “Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling.”

“Our results showed that a subset of T cells, labeled as CD8-fit T cells, are capable of high motility and serial killing, found uniquely in patients with clinical response,” says first author and recent UH graduate Ali Rezvan in Nature Cancer.

Besides him and Varadarajan, contributors hail from Baylor College of Medicine/Texas Children’s Hospital, MD Anderson Cancer Center, Kite Pharma, and CellChorus itself.

The team identified the CD80-fit T cells using TIMING to examine interactions between T cells and tumor cells across thousands of individual cells. They were able to integrate the results using single-cell RNA sequencing data.

T-cell therapy activates a patient’s own immune system to fight cancer cells, but not every patient responds favorably to it. Identifying CD8-fit cells could be the key to manufacturing clinical response even in those for whom immunotherapy hasn’t been effective.

“This work illustrates the excellence of graduate students Ali Rezvan and Melisa Montalvo; and post-doctoral researchers Melisa Martinez-Paniagua and Irfan Bandey among others,” says Varadarajan in a statement.

Earlier last month, CellChorus recently received a $2.5 million SBIR grant. The money allows the company to share TIMING more widely, facilitating even more landmark discoveries like CD8-fit cells.

CellChorus, a biotech startup operating out of the University of Houston Technology Bridge, has secured fresh funding. Photo via Getty Images

Houston biotech startup secures $2.3M grant

cha-ching

They say it’s all in the timing. For CellChorus, it’s all in the TIMING. That’s Time-lapse Imaging Microscopy In Nanowell Grids. TIMING is a visual AI program that evaluates cell activation, killing and movement, which allows scientists to better understand how cells function.

The technology is important to the development of novel therapies in the realms of oncology, infectious diseases, and countless other disorders and diseases. By allowing scientists to observe those maladies at their roots, it will enable them to create, and ultimately deliver new medications and other therapies faster, at lower cost, and with a higher success rate.

CellChorus is a spinoff of the Single Cell Lab at the University of Houston. Part of UH’s Technology Bridge, CEO Daniel Meyer connected with co-founder and leader of Single Cell Lab, Navin Varadarajan, through co-founder Laurence Cooper.

“The company had been established, but there were limited operations,” recalls Meyer during a phone call with InnovationMap.

That was the fall of 2020. Now, the team has just announced a $2.3 million SBIR (Small Business Innovation Research) Fast-Track grant from the National Institute of General Medical Sciences.

“This funding will support development of a product offering that builds on the success of our early access laboratory,” Cooper said in a press release. “As the next frontier of cellular analysis, dynamic single-cell analysis will increase the impact that immunotherapies have in improving the lives of patients.”

Meyer is based in the Bay Area, but the rest of the team is in Houston. Meyer has a proven track record as an investor and early stage entrepreneur in life sciences companies, including work as COO of Genospace, which was acquired by HCA Healthcare.

Meyer says that what attracted him to CellChorus was a combination of a clear need for the technology and the fact that it was “very well validated.“

“Developers of immunotherapies need better functional data earlier so that they can develop and deliver better therapies,” he explains.

Another aspect of its appeal was the fact that more than 10 publications featured data from the TIMING platform.

“We’ve had both large and small biopharmas publish data,” says Meyer. “That’s important as well because it shows there’s applicability in both nonprofit and for-profit research.”

Though Meyer himself doesn’t currently live in Houston, he recognizes its importance to CellChorus. He says that it can be difficult for an early stage company to find appropriate lab space, so Technology Bridge was of exceptional importance for CellChorus. Since opening the lab a year and a half ago, Varadarajan and his team have been busy.

“Example projects we have completed include understanding mechanism of action for cell therapy products, selecting lead candidates for T cell engagers, identifying biomarkers of response to cell therapies, and quantifying potency and viability for cell therapy manufacturing technologies,” says Meyer.

And now, CellChorus is collaborating with leaders in the industry.

“These include top-25 biopharmaceutical companies and promising venture-backed biotechnology companies, as well as leading not-for-profit research institutions,” says Meyer in a press release. It’s clear that the TIMING is right for CellChorus to excel.

UH and a local company are developing a new COVID-19 vaccine. Photo by Getty Images

University of Houston partners with local company to develop cutting-edge COVID vaccine

COOGS TACKLE COVID

A major Houston university has taken a big leap in the race to battle debilitating diseases such as COVID-19. The University of Houston has entered into an exclusive license option agreement with AuraVax Therapeutics Inc., a Houston-based biotech company developing novel vaccines against aggressive respiratory diseases such as coronavirus, according to a press release.

This means AuraVax has the option to exclusively license a new intranasal COVID-19 vaccine technology developed by Navin Varadarajan, an M.D. Anderson professor of chemical and biomolecular engineering. Varadarajan is a co-founder of AuraVax.

The vaccine is a nasal inhalant, much like FluMist. Based on pre-clinical experimentation, Varadarajan reports his technology not only elicits a mucosal immune response, but also systemic immunity, according to UH.

"We plan to stop COVID-19, a respiratory virus, at its point of entry — the nasal cavity — and we believe our intranasal platform is a differentiated approach that will lead to a vaccine with increased efficacy to create sustained immunity to COVID-19," said Varadarajan in a statement.

So how does it work? Varadarajan is utilizing the spike protein, which helps the virus enter the target cell, and is the major target for neutralizing antibodies as it binds to the ACE 2 cellular receptor, for virus entry. The professor prefers using proteins because of their ability to induce strong immune responses, flexibility and scalability, and the absence of infectious particles, per UH.

Varadarajan's company, AuraVax, has created a next-generation vaccine platform that combines the potential of in-home administration with the ability to deliver complete immunity. The technology has been validated for COVID-19 in initial animal studies and results in immunity measured by both B-cell and T-cell responses.

"We believe AuraVax has a competitive advantage given the immune responses and a supply chain that is well-suited for widespread distribution and self-administration distribution," said Varadarajan. "We are excited to be collaborating with the University of Houston and look forward to future success by advancing the development of this novel intranasal vaccine technology to address a multitude of respiratory viruses, starting with COVID-19."

------

This article originally ran on CultureMap.

The University of Houston, a Tier One research institution, has a few ongoing projects focusing on treating or preventing COVID-19. Photo courtesy of University of Houston

University of Houston researchers studying COVID-19 prevention and treatment

research roundup

Researchers across the country are focusing on all things COVID-19 — from biotherapies and treatment to vaccines and prevention. A handful of researchers based out of the University of Houston are doing their best to move the needle on a cure or reliable vaccine.

Here are three research projects currently ongoing at UH.

UH pharmacy professors take it back to basics

UH College of Pharmacy professors Gomika Udugamasooriya (left) and Bin Guo are studying how the virus enters the human body. Photo via uh.edu

When thinking about how to prevent the spread of COVID-19, two UH pharmacy professors are looking at how the virus enters the body. Then, this information can help develop protection of that entry point.

"The human entry of coronaviruses depends on first binding of the viral spike proteins to human cellular receptors that basically offer a cellular doorknob," says Gomika Udugamasooriya, associate professor of pharmacological and pharmaceutical sciences, in a press release. "The virus latches onto the specific human cellular receptor, ACE2, and sneaks inside to replicate itself within the cell to spread throughout the body."

Now, the goal of new drugs and vaccines is to protect that ACE2. Udugamasooriya is working with Bin Guo, associate professor of pharmaceutics, on this research, which is in the initial screening levels and identified drug-lead validations. They are working to apply their unique cell-screening technology to identify specific synthetic chemical drug leads called peptoids that can bind to ACE2 receptor, according to the release.

"Peptoids are easier to make, compatible with biological systems and economical to produce," says Udugamasooriya.

Duo aims to create inhalation vaccine for COVID-19

Navin Varadarajan, UH engineering professor (left), and pharmaceutics professor Xinli Liu, pharmaceutics professor, are collaborating on development and testing of a COVID-19 inhalation vaccine. Photo via uh.edu

If the disease itself is airborne, can't the vaccine be too? That's what M.D. Anderson Associate Professor of Chemical and Biomolecular Engineering Navin Varadarajan looking into.

"For airborne pathogens, the nasal mucosa is the first point of defense that needs to be breached," says Varadarajan in a news release. "Mucosal immunity and vaccines are fundamentally important for a wide range of pathogens including influenza, severe acute respiratory syndrome coronavirus (SARS-CoV) and the current SARS-CoV-2."

Varadarajan is focusing on the spike protein to protect at virus entry. These proteins are known for building strong immune responses, flexibility and scalability, and absence of infectious particles. He is working with Xinli Liu, associate professor of pharmaceutics.

"As with any vaccine, a variety of factors determine their efficacy including the antigen used for electing a response, the adjuvants and immunomodulators, the efficient delivery of the antigen to appropriate target cells, and the route of vaccination," Varadarajan says.

The man with three different vaccine options

UH Professor Shaun Zhang is in the process of developing three COVID-19 vaccine candidates for injection. Photo via uh.edu

Shaun Zhang, director for the Center for Nuclear Receptors and Cell Signaling, usually works on developing treatment or vaccines for cancer and viral infection. Now, he's switched gears to work on three different vaccine candidates for COVID-19.

"The data collected from our studies show that our vaccine candidates can generate neutralizing antibodies, which can protect cells from infection by SARS-CoV-2 when tested in vitro," says Zhang in a press release. "We are now working on further improvement for the vaccine design."

Zhang's approach is neutralizing antibody production, and he's tapped into using "subunit vaccine containing either the entire spike protein or the receptor binding portion, which helps the virus enter the target cell, and delivered either by DNA formulation or by a herpes simplex virus-based vector," according to the release. Low cost and simplicity are two priorities for Zhang's work.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Meet the esteemed judges for the 2026 Houston Innovation Awards

Meet The Judges

Editor's note: Judging is now underway for the 2026 Houston Innovation Awards, and it's time to meet the decision makers.

Our 2026 judging panel comprises past award winners who represent a variety of industries and areas of expertise. They are joined by InnovationMap's interim editor. All are deeply engaged in the Houston innovation ecosystem.

Our judging panel will review all nominee applications submitted across 10 prestigious categories. They will determine the 2026 finalists in all categories, and they will select the winners in all but one category — our people's choice award for Startup of the Year.

The sixth annual Houston Innovation Awards program will be presented in an all-digital format in 2026. We will announce this year's finalists and feature their stories throughout our special editorial series this fall. Then, stay tuned as we reveal the 2026 Houston Innovation Awards winners on InnovationMap.com in mid-November.

Sagar Dalal, Fervo Energy, 2025 Scaleup of the Year

Sagar Dalal serves as chief of staff at Fervo Energy, a company pioneering the commercialization of next-generation geothermal power. In this role, he helps translate the CEO’s vision and priorities into execution, leading cross-functional strategic initiatives that support the company’s growth and operations.

Dalal brings nearly eight years of experience in structural engineering and project management from his time at Thornton Tomasetti and Tesla, where he engineered and built a wide range of infrastructure projects ranging from stadiums to manufacturing facilities. He holds an MBA from Stanford University and an MS in Civil Engineering from Texas A&M University. He is also a licensed professional engineer.

Aaron Fitzgerald, Mars Materials, 2025 Minority-founded Business of the Year

Aaron Fitzgerald is a three-time founder and carbon removal entrepreneur focused on reimagining how we make things. As the CEO of Mars Materials, he leads a team working to commercialize technologies that sequester captured carbon into industrial supply chains.

His vision for a defossilized future is shaped by a unique path through both policy, including a tenure in the United States Senate, and deep carbontech, with fellowships at The Lewis Latimer program, Breakthrough Energy, Prime Coalition, and Carbon 180.

Tatiana Fofanova, Koda Health, 2025 Health Tech Business of the Year

Tatiana Fofanova, PhD, is the co-founder and CEO of Koda Health, an AI-enhanced patient decision support platform designed to make advance care planning (ACP) scalable, accessible, and patient-centered for patients with serious illness.

After earning her PhD in Translational Medicine at Baylor College of Medicine, she joined Texas Medical Center (TMC) as a Founder-in-Residence. It was there that she and her co-founders identified one of the most overlooked yet critical gaps in healthcare: the lack of meaningful, accessible advance care planning. Under her leadership, Koda Health now supports over 1 million patients through partnerships with organizations like Cigna, Privia, and Houston Methodist.

Lawson Gow, Greentown Labs, 2025 Incubator/Accelerator of the Year

Lawson Gow currently serves as chief strategy officer for Greentown Labs, which was named Incubator/Accelerator of the Year in the 2025 Houston Innovation Awards. Prior to joining Greentown Labs as Head of Houston in 2025, Gow was as a managing partner at Helium Capital, an investment and advisory firm that aims to support founders across the entire lifecycle of entrepreneurship.

He is also the founder of The Cannon, an innovation-infrastructure provider that operates a growing network of innovation hubs for its community of startups, entrepreneurs, investors, and corporate innovators.

Sarah Hein, March Biosciences, 2025 Female-founded Business of the Year

Sarah Hein is the founding CEO of March Biosciences, a clinical-stage cell-therapy company targeting challenging malignancies. Prior to cofounding March Biosciences, she was the founding Entrepreneur in Residence for the Texas Medical Center Innovation Accelerator for Cancer Therapeutics (TMCi ACT).

Formerly, she was a cofounder and the vice president of operations at Courier Therapeutics, a cancer immunotherapy startup acquired by Valo Health. She was also director of research at Resonant Therapeutics, an antibody therapeutics platform technology company. She began at Mercury Fund as a Venture Fellow directly after graduating with her PhD in Molecular Biology from Baylor College of Medicine.

Tanu Jain, FlowCare, 2025 Startup of the Year

Tanu Jain is a product executive, entrepreneur, founder and CEO of FlowCare, and registered nurse with a track record of building products from zero to global scale. She previously led product at BioIQ before founding FlowCare, a Houston-based period care infrastructure platform making period care a standard in every restroom. In under 16 months, FlowCare has signed deployed across four enterprise customers and impacted more than 1.5 million women.

FlowCare was named Startup of the Year at the 2025 Houston Innovation Awards, and Jain has been recognized with additional honors including the SDG Super Changemaker – Pewter — at the Global Sustainability Awards 2026.

Prabhdeep "Prab" Sekhon, Eclipse Energy, 2025 Energy Transition Business of the Year

Prabhdeep Singh Sekhon is CEO of Eclipse Energy, an energy technology company transforming depleted oil fields into low-cost, sustainable hydrogen resources through subsurface biotechnology. He brings nearly two decades of global energy experience spanning climate technology, venture capital, private equity, and multi-billion-dollar energy projects across five continents.

Previously, he held leadership roles at NextEra Energy Resources and Hess Corporation. He is also a founder and managing director of GreenLite Resources and a founding member of Cotogna Sports Group. He holds an MBA from Wharton, a Masters in Engineering from Texas A&M, and a BS from the University of Calgary.

Wade Pinder, Product Houston, 2025 Trailblazer Award Winner

Wade Pinder thinks of himself as an "ecosystem wayseeker," helping founders and builders in and around Houston find their footing, understand the landscape, and move through uncertainty with more clarity. Through Product Houston, he works at the intersection of product strategy, founder support, ecosystem mapping, and community-building, with a particular focus on helping people show up in the right rooms before they feel fully ready.

His background includes years in product management at Blinds.com and Home Depot, along with founding and leading the Houston Product Community for six years. He was recognized by as Mentor of the Year in the 2023 Houston Innovation Awards and received the Trailblazer Award in 2025.

Laura Furr Mericas, Interim Editor, InnovationMap

Laura Furr Mericas is interim editor for InnovatonMap.com and EnergyCapitalHTX.com. She is a longtime contributor to both sites and has reported on Houston's innovation ecosystem for InnovationMap since 2020. Previously, she served as web editor and data reporter for Houston Business Journal.

Report: Income for top 1 percent earners in Texas has surged in 2026

money matters

In a state where local billionaires are wealthier than they've ever been, high-earning Texans need to make $73,000 more than they did a year ago if they want to be among the top 1 percent of earners, a new report has revealed.

SmartAsset's study analyzed income thresholds for the top 1, 5, and 10 percent of earners in all 50 states and the District of Columbia, using 2022 IRS data for individual tax return filers (the most recent year available), adjusted to 2026 dollars.

Texas has the 11th highest income threshold, with residents needing to make a minimum of $817,158 to be considered among the top 1 percent of earners statewide. In 2025, Texans needed to make about $744,000 to be among the top 1 percent.

For comparison, residents living in the nation's capital must make at least $1.16 million to qualify as top 1 percent earners. The District of Columbia led the nation with the highest income threshold to be a top earner.

To be considered among the top 5 percent of earners in Texas, a resident would need to make $312,671. The income threshold to be considered among the top 10 percent is $210,609.

SmartAsset additionally found that 128,130 Texas residents qualified as top 1 percent earners in 2022. Nationally, the report estimated that fewer than 2 million households earn enough to be considered among the top 1 percent of earners nationwide, but 23 million households rank among the top 10 percent.

"In some places, households can enter the top 1 percent at income levels that fall well below the threshold elsewhere, reflecting an uneven landscape of wages and wealth," the report said.

A separate SmartAsset study that tracked the upper and lower thresholds for middle class households found Houston residents need to make anywhere from $42,907 to $128,722 to maintain their middle class status.

The top 10 states with the highest thresholds to be considered in the top 1 percent of earners in the U.S. are:

No. 1 – District of Columbia ($1,156,664)
No. 2 – Connecticut ($1,147,898)
No. 3 – Massachusetts ($1,006,921)
No. 4 – California ($987,325)
No. 5– New Jersey ($969,976)
No. 6 – New York ($959,562)
No. 7 – Florida ($956,449)
No. 8 – Washington ($903,303)
No. 9 – Colorado ($828,772)
No. 10 – Wyoming ($819,014)

---

This article originally appeared on CultureMap.com.

Here’s where wages grew the most in Houston since 2021, according to new report

pay raise

Bolstered by a thriving manufacturing sector, Waller County—the country’s second-fastest-growing county—leads all Houston-area counties for the growth of pay from 2021 to 2026, according to a new study.

The study, conducted by personal finance website SmartAsset, found average pay in Waller County rose 48 percent from 2021 to 2026. The county’s average weekly pay climbed from $891 to $1,323 during that period.

Manufacturing ranks as the No. 1 employment sector in Waller County, accounting for about 4,500 workers, according to Executive Pulse. Those workers earn an average pay of $77,442 per year.

Waller County powers up its manufacturing hub

Waller County’s manufacturing economy keeps expanding, almost certainly contributing to the 48 percent spike in average pay from 2021 to 2026.

Grundfos, the world’s largest producer of water pumps, broke ground in June on a manufacturing plant at its Brookshire campus. The Danish company’s U.S. headquarters is in Brookshire. In conjunction with the groundbreaking, Grundfos opened the Grundfos Academy Americas training center.

The new 143,000-square-foot facility will make pump systems and water technology, primarily for water utilities and commercial real estate landlords.

Grundfos expects construction to be completed by Q3 2027, with the first production lines planned to start in Q4 of next year.

“Our growing presence in Brookshire reflects both our confidence in the U.S. market and our long‑term commitment to investing where our customers and partners need us most,” Grundfos CEO Poul Due Jensen said in a release.

Another manufacturer, TMEIC Corporation America, recently opened its third U.S. plant at Twinwood Business Park in Brookshire. The 280,000-square-foot facility, which eventually might employ 500 people, makes uninterruptible power supply units and medium-voltage power drives. The $65 million plant includes a customer training center and tech development labs.

The Twinwood facility is the largest of TMEIC’s 13 factories around the world.

TMEIC’s two other U.S. manufacturing plants are in the Houston area. The company’s North American headquarters is in the Houston Energy Corridor.

Perhaps the biggest recent manufacturing prize for Waller County: Austin-based electric vehicle maker Tesla’s new 1.65 million-square-foot factory at Brookshire’s Empire West Industrial Park. The $200 million plant, expected to employ up to 1,500 people by 2028, produces utility-scale batteries for energy storage.

Other major manufacturers in Waller County include Daikin North America and Igloo.

Pay growth around the region

Here’s a rundown of 2021-26 pay growth in the Houston metro’s eight other counties, according to SmartAsset.

Austin County — 42 percent
Chambers County — 37 percent
Harris County — 33 percent
Liberty County — 31 percent
Montgomery County — 29 percent
Fort Bend County — 28 percent
Galveston County — 26 percent
Brazoria County — 23 percent

Statewide, Dickens County, outside of Lubbock, saw the most significant growth in wages. According to the study, wages grew by 212 percent over the five years, from $707 per week in 2021 to $2,204 per week in 2026.

Among all Texas counties, Waller was ranked No. 44 on the report.

Small counties in the High Plains and West Texas regions saw the largest percent changes in average weekly wage, according to the report. See the full findings here.

View All Listings

INNOVATIONMAP EMAILS ARE AWESOME